Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Once a Day Dose Compared to 2 Doses/Day

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of ulcerative colitis that has been successfully maintained in remission for at least 3 months prior to study entry~* At least one flare in the past 18 months~* Utilizing a stable maintenance dose of oral Asacol of 1.6 g/day up to 2.4 g/day (stable dose is defined as the same dose for the past 3 months)~* Females must be postmenopausal or surgically sterile or have a negative urine pregnancy test and practice acceptable contraception~Exclusion Criteria:~* History of or current renal disease~* History of hepatic disease~* History of allergy or hypersensitivity to salicylates, aminosalicylates~* Treatment with immunomodulatory therapy, biologic therapy or corticosteroids within 90 days of screening~* Received any antidiarrheals, antispasmodics, or antibiotic within 1 month of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mesalamine (Asacol) Once-Daily (Type: ACTIVE_COMPARATOR): an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day)
- Mesalamine (Asacol) Twice-Daily (Type: ACTIVE_COMPARATOR): an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).